Scarica l'app Stockscreener
0.168
21.52%
-0.042
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.21
Aprire:
$0.16625
Volume 24 ore:
17,706
Relative Volume:
21.48
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
$-16.08M
Rapporto P/E:
-0.00488
EPS:
-34.43
Flusso di cassa netto:
$-11.54M
1 W Prestazione:
-21.52%
1M Prestazione:
-80.61%
6M Prestazione:
-86.27%
1 anno Prestazione:
-97.18%
Intervallo 1D:
$0.1629
$0.1699
Intervallo di 1 settimana:
$0.1629
$0.1699
Portata 52W:
$0.1629
$0.1699
Bio Path Holdings Inc Stock (BPTH) Company Profile
Nome
Bio Path Holdings Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta BPTH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
0.168 | 0 | 0 | -16.08M | -11.54M | -34.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-03-11 | Iniziato | ROTH Capital | Buy |
| 2017-11-13 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-10 | Reiterato | Maxim Group | Buy |
| 2016-04-18 | Iniziato | Rodman & Renshaw | Buy |
| 2014-06-02 | Ripresa | Maxim Group | Buy |
| 2014-05-09 | Iniziato | Maxim Group | Buy |
Mostra tutto
Bio Path Holdings Inc Borsa (BPTH) Ultime notizie
Cutaneous T Cell Lymphoma Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED
Life Sciences Investor Forum: Now Available for Online Viewing - The Manila Times
GitLab (NASDAQ:GTLB) Given New $60.00 Price Target at Wells Fargo & Company - Defense World
GRI Bio’s (GRI) Buy Rating Reaffirmed at HC Wainwright - Defense World
Short Interest in Bitcoin Depot Inc. (NASDAQ:BTMWW) Expands By 5,350.0% - Defense World
GitLab (NASDAQ:GTLB) Price Target Cut to $52.00 by Analysts at JPMorgan Chase & Co. - Defense World
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Up 870.6% in May - Defense World
Two Sigma Investments LP Cuts Position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) - Defense World
Two Sigma Investments LP Reduces Stock Holdings in Industrial Logistics Properties Trust (NASDAQ:ILPT) - Defense World
Two Sigma Investments LP Makes New $273,000 Investment in ORIX Co. (NYSE:IX) - Defense World
Life Sciences Investor Forum Agenda Announced for June 11th-12th - GlobeNewswire
Bio-Path Holdings to Present at Life Sciences Virtual Investor F - GuruFocus
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum | BPTH Stock News - GuruFocus
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum - The Manila Times
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia - The Manila Times
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i - The Manila Times
Bio-Path Showcases Revolutionary DNAbilize Cancer Treatment: Phase 2 Results Coming - Stock Titan
Roth Capital Issues Negative Estimate for Bio-Path Earnings - Defense World
Roth Capital Forecasts Bio-Path FY2029 Earnings - Defense World
“Intel Foundry Will Need to Earn (Intel’s) Business”: Intel Stock (NASDAQ:INTC) Slips as Intel Looks for Better Deal Than Intel - The Globe and Mail
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25 | BPTH Stock News - GuruFocus
When is Comtech's Q3 Earnings? Key Date and Conference Call Details Revealed - Stock Titan
Oil-Dri Delivers Massive 16% Dividend Hike After 22 Years of Unbroken Growth - Stock Titan
Bio-Path's Breakthrough: Phase 2 Leukemia Drug Advances While New Cancer Treatments Show Promise - Stock Titan
Royalty Pharma to Share Strategic Updates at Goldman Sachs Healthcare Conference 2025 - Stock Titan
ChargePoint Q1 Earnings Show 31% Margins, Eaton Partnership Powers New Growth Strategy - Stock Titan
Roth Capital Lowers Bio-Path (BPTH) PT to $2 Amidst Pipeline Updates, Liquidity Concerns - Insider Monkey
Q.ANT Debuts First Interactive Live Demonstration and New Benchmarks for Analog Photonic Computing at ISC 2025 - Newsfile
Bio-Path's (BPTH) Price Target Reduced by Roth Capital Amid Pipe - GuruFocus
Bio-Path's (BPTH) Price Target Reduced by Roth Capital Amid Pipeline Updates | BPTH Stock News - GuruFocus
BPTH: Bio-Path's Latest Clinical Developments and Milestones | B - GuruFocus
Robinhood Markets Hits 52-Week High: Should You Buy the Stock Now? - The Globe and Mail
Bio-Path Holdings Provides Clinical and Operational Update | BPT - GuruFocus
BPTH: Bio-Path's Latest Clinical Developments and Milestones | BPTH Stock News - GuruFocus
Bio-Path Holdings Provides Clinical and Operational Update - The Manila Times
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib - The Manila Times
Bio-Path Holdings Provides Clinical and Operational Update | BPTH Stock News - GuruFocus
Bio-Path Holdings, Inc. Provides Update on Clinical Development Progress and Pipeline Advances - Nasdaq
Bio-Path Clinical Trial Breakthrough: Cancer Patients Achieve Complete Remission After 15+ Treatment Cycles - Stock Titan
Auric Minerals Corp. Announces Closing of Property Transaction - The Globe and Mail
Blokees made its debut at CCXP México 2025, Officially Enters México Market - The Globe and Mail
Colgate-Palmolive Reshapes Executive Team: Danone Deputy CEO Joins as Americas COO in Strategic Growth Push - Stock Titan
Cytokinetics Management Reveals Latest Updates at Jefferies Healthcare ConferenceLive Webcast Available - Stock Titan
Transcript : Bio-Path Holdings, Inc.Special Call - marketscreener.com
Toyota Signs Rising Latin Star Ela Taubert as Tour Sponsor: Major US Concert Series Coming - Stock Titan
Revolutionary AI Nose Technology Hits 85% Accuracy, Targets $76.5B SmellTech Market for Eldercare Crisis - Stock Titan
Biotech to AI: Bionoid Pharma Makes Bold Pivot with New Identity as AI Maverick Intel - Stock Titan
Lantronix Launches Revolutionary AI Network Manager for $400M Console Server Market at Cisco Live - Stock Titan
Zacks Industry Outlook Highlights Tetra Tech, Atmus Filtration Technologies, Energy Recovery and LiqTech International - The Globe and Mail
Gentherm Leadership Team Announces Packed Schedule: 3 Key Investor Conferences Coming in June 2025 - Stock Titan
Bio Path Holdings Inc Azioni (BPTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.10%
1.57%
Capitalizzazione:
|
Volume (24 ore):